$1.91 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter

Wall Street analysts expect that Celldex Therapeutics, Inc. (NASDAQ:CLDX) will post sales of $1.91 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Celldex Therapeutics’ earnings, with the highest sales estimate coming in at $2.11 million and the lowest estimate coming in at $1.70 million. Celldex Therapeutics posted sales of $1.87 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 2.1%. The company is expected to issue its next earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that Celldex Therapeutics will report full-year sales of $1.91 million for the current fiscal year, with estimates ranging from $9.30 million to $11.40 million. For the next year, analysts anticipate that the business will post sales of $13.57 million per share, with estimates ranging from $100,000.00 to $34.10 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Celldex Therapeutics.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.07. The business had revenue of $3.90 million for the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The firm’s revenue was up 77.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.29) EPS.

Several equities research analysts recently commented on CLDX shares. HC Wainwright reaffirmed a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. WBB Securities reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.05.

Celldex Therapeutics (NASDAQ CLDX) traded down $0.04 on Wednesday, reaching $2.88. 659,882 shares of the company traded hands, compared to its average volume of 1,640,297. The company has a market cap of $397.08, a PE ratio of -2.85 and a beta of 2.71. Celldex Therapeutics has a 1-year low of $2.20 and a 1-year high of $4.02.

A number of large investors have recently modified their holdings of CLDX. Vanguard Group Inc. lifted its position in Celldex Therapeutics by 7.8% during the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after buying an additional 708,095 shares in the last quarter. Meditor Group Ltd lifted its position in Celldex Therapeutics by 8.8% during the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after buying an additional 512,700 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Celldex Therapeutics by 426.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 492,547 shares of the biopharmaceutical company’s stock worth $1,778,000 after buying an additional 398,978 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Celldex Therapeutics during the 2nd quarter worth about $943,000. Finally, Russell Investments Group Ltd. lifted its position in Celldex Therapeutics by 741.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 352,511 shares of the biopharmaceutical company’s stock worth $1,008,000 after buying an additional 310,638 shares in the last quarter. 52.46% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/27/1-91-million-in-sales-expected-for-celldex-therapeutics-inc-cldx-this-quarter.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

What are top analysts saying about Celldex Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celldex Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit